Encephalitis, tick borne suspension for injection is indicated for the active (prophylactic) immunization of persons of 16 years of age and older against tick-borne encephalitis (TBE). Its pharmacodynamic effect consists of the induction of a sufficiently high concentration of anti-TBE antibody to provide protection against the TBE virus.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07BA01 | Encephalitis, tick borne, inactivated, whole virus | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BA Encephalitis vaccines |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TICOVAC Suspension for injection in a pre-filled syringe | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Encephalitis, tick borne is an active ingredient of these brands:
Austria (AT)
Croatia (HR)Ireland (IE)Israel (IL)Malta (MT)Netherlands (NL)Poland (PL)
Romania (RO)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
